Trial Profile
A study investigating the effect of maraviroc on CD16-expressing monocytes in patients with HIV-associated neurocognitive disease and receiving combination antiretroviral therapy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2015
Price :
$35
*
At a glance
- Drugs Maraviroc (Primary)
- Indications HIV infections; Neurological disorders
- Focus Therapeutic Use
- 09 Dec 2015 New trial record